On July 26, 2024, Bristol-Myers Squibb Company (BMS) released its financial results for the second quarter of 2024, showcasing a 9% increase in revenues to $12.2 billion, with an 11% rise when adjusted for foreign exchange impacts. The growth was primarily driven by the company's Growth Portfolio and the drug Eliquis. U.S. revenues saw a 13% increase, while international revenues experienced a slight decline due to foreign exchange impacts. GAAP EPS was reported at $0.83, with Non-GAAP EPS at $2.07, reflecting net impacts from acquired IPRD charges and licensing income. The company also highlighted the U.S. approval of Breyanzi for follicular lymphoma and mantle cell lymphoma, and the ongoing regulatory review of subcutaneous Nivolumab in the U.S. and E.U. Additionally, BMS raised...Show More

On July 26, 2024, Bristol-Myers Squibb Company (BMS) released its financial results for the second quarter of 2024, showcasing a 9% increase in revenues to $12.2 billion, with an 11% rise when adjusted for foreign exchange impacts. The growth was primarily driven by the company's Growth Portfolio and the drug Eliquis. U.S. revenues saw a 13% increase, while international revenues experienced a slight decline due to foreign exchange impacts. GAAP EPS was reported at $0.83, with Non-GAAP EPS at $2.07, reflecting net impacts from acquired IPRD charges and licensing income. The company also highlighted the U.S. approval of Breyanzi for follicular lymphoma and mantle cell lymphoma, and the ongoing regulatory review of subcutaneous Nivolumab in the U.S. and E.U. Additionally, BMS raised its 2024 Non-GAAP guidance. The financial report included details on product revenue highlights, with significant growth in the sales of Opdivo, Reblozyl, Camzyos, and Opdualag, while Abecma sales declined. The Legacy Portfolio also showed growth, driven by Eliquis and Pomalyst, despite a decline in Revlimid due to generic erosion. BMS also provided updates on clinical and regulatory milestones, including approvals and trial results for various treatments. The company emphasized its commitment to operational excellence and growth potential, with a focus on patient impact and upcoming product launches.